CU20110067A7 - Péptidos cíclicos con actividad antineoplásica y antiangiogénica - Google Patents
Péptidos cíclicos con actividad antineoplásica y antiangiogénicaInfo
- Publication number
- CU20110067A7 CU20110067A7 CU2011000067A CU20110067A CU20110067A7 CU 20110067 A7 CU20110067 A7 CU 20110067A7 CU 2011000067 A CU2011000067 A CU 2011000067A CU 20110067 A CU20110067 A CU 20110067A CU 20110067 A7 CU20110067 A7 CU 20110067A7
- Authority
- CU
- Cuba
- Prior art keywords
- cyclic peptides
- antineoplassic
- antiangiogenic activity
- systems
- nanobiotechnology
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a péptidos cíclicos con propiedades antitumorales y antiangiogénicas, así como a sus sales farmacéuticamente aceptables y a las composiciones farmacéuticas que los contienen. Estos péptidos cíclicos se emplean en la preparación de medicamentos para la terapéutica humana y/o veterinaria, y también pueden emplearse en el diagnóstico. Estos compuestos pueden ser usados para detectar, monitorear y/o controlar una variedad de desórdenes relacionados con la proliferación celular, tales como las enfermedades oncológicas y la angiogénesis no deseada. Además, pueden formar parte de sistemas de liberación controlada y en el campo de la nanobiotecnología, ya sea por su capacidad de autoensamblaje o como parte de otros sistemas.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2011000067A CU23950B1 (es) | 2011-03-21 | 2011-03-21 | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
CN201280021627.4A CN103534265B (zh) | 2011-03-21 | 2012-03-21 | 具有抗肿瘤形成和抗血管生成活性的环肽 |
ARP120100930A AR088727A1 (es) | 2011-03-21 | 2012-03-21 | Peptidos ciclicos con actividad antineoplasica y antiangiogenica |
RU2013146690/10A RU2603286C2 (ru) | 2011-03-21 | 2012-03-21 | Циклические пептиды с антинеопластической и антиангионенной активностью |
ES12716190.9T ES2644554T3 (es) | 2011-03-21 | 2012-03-21 | Péptidos cíclicos con actividad antiangiogénica y antineoplásica |
JP2014500249A JP6032854B2 (ja) | 2011-03-21 | 2012-03-21 | 抗新生物及び抗血管新生活性を有する環状ペプチド |
BR112013024265-5A BR112013024265B1 (pt) | 2011-03-21 | 2012-03-21 | peptídeos cíclicos, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica |
PCT/CU2012/000002 WO2012126441A2 (es) | 2011-03-21 | 2012-03-21 | Péptidos cíclicos con actividad antineoplásica y antiangiogénica. |
AU2012231427A AU2012231427B2 (en) | 2011-03-21 | 2012-03-21 | Cyclic peptides with an anti-neoplasic and anti-angiogenic activity |
MX2013010813A MX348677B (es) | 2011-03-21 | 2012-03-21 | Peptidos ciclicos con actividad antineoplasica y antiangiogenica. |
KR1020137027692A KR101958964B1 (ko) | 2011-03-21 | 2012-03-21 | 항종양 및 항혈관생성 활성을 갖는 사이클릭 펩타이드 |
EP12716190.9A EP2690107B1 (en) | 2011-03-21 | 2012-03-21 | Cyclic peptides with an anti-neoplasic and anti-angiogenic activity |
US14/005,855 US9375459B2 (en) | 2011-03-21 | 2012-03-21 | Cyclic peptides with an anti-neoplasic and anti-angiogenic activity |
CA2830325A CA2830325C (en) | 2011-03-21 | 2012-03-21 | Cyclic peptides with an anti-neoplasic and anti-angiogenic activity |
ZA2013/07037A ZA201307037B (en) | 2011-03-21 | 2013-09-18 | Cyclic peptides with an anti-neoplastic and anti-angiogenic activity |
CO13248567A CO6801641A2 (es) | 2011-03-21 | 2013-10-21 | Péptidos cíclicos con actividad con actividad antineoplásica y antiangiogénica |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2011000067A CU23950B1 (es) | 2011-03-21 | 2011-03-21 | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20110067A7 true CU20110067A7 (es) | 2012-10-15 |
CU23950B1 CU23950B1 (es) | 2013-10-29 |
Family
ID=46000593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2011000067A CU23950B1 (es) | 2011-03-21 | 2011-03-21 | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
Country Status (16)
Country | Link |
---|---|
US (1) | US9375459B2 (es) |
EP (1) | EP2690107B1 (es) |
JP (1) | JP6032854B2 (es) |
KR (1) | KR101958964B1 (es) |
CN (1) | CN103534265B (es) |
AR (1) | AR088727A1 (es) |
AU (1) | AU2012231427B2 (es) |
BR (1) | BR112013024265B1 (es) |
CA (1) | CA2830325C (es) |
CO (1) | CO6801641A2 (es) |
CU (1) | CU23950B1 (es) |
ES (1) | ES2644554T3 (es) |
MX (1) | MX348677B (es) |
RU (1) | RU2603286C2 (es) |
WO (1) | WO2012126441A2 (es) |
ZA (1) | ZA201307037B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9683018B2 (en) * | 2013-07-25 | 2017-06-20 | Novartis Ag | Disulfide cyclic polypeptides for the treatment of heart failure |
KR20160031551A (ko) * | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
MX2016001021A (es) * | 2013-07-25 | 2016-08-03 | Novartis Ag | Bioconjugados de polipeptidos de apelina sinteticos. |
EP3024846A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
CA2945945C (en) | 2014-04-15 | 2023-10-03 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
CN109503701B (zh) * | 2018-07-20 | 2022-03-15 | 北京工业大学 | 一种环肽及其在制备抗肿瘤药物中的应用 |
CN111662363A (zh) * | 2020-06-22 | 2020-09-15 | 上海大学 | 环肽类抗肿瘤活性化合物及其制备方法与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003264192A1 (en) * | 2002-08-30 | 2004-03-19 | Biopharmacopae Design International Inc. | Plant extracts for treatment of angiogenesis and metastasis |
CU23475A1 (es) * | 2004-07-08 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas |
WO2007022557A1 (en) * | 2005-08-23 | 2007-03-01 | Diatech Pty Ltd | Mimotopes of epstein-barr virus (ebv) epitopes |
WO2007044668A2 (en) * | 2005-10-08 | 2007-04-19 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
ITTO20060852A1 (it) * | 2006-11-30 | 2008-06-01 | Univ Degli Studi Torino | Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche |
CN102264755A (zh) * | 2007-08-08 | 2011-11-30 | 得克萨斯大学体系董事会 | 靶向vegfr-1/nrp-1的肽 |
EP2303913A4 (en) * | 2008-06-20 | 2013-07-24 | Univ Texas | TARGETING PEPTIDES OF CRKL |
US20100015058A1 (en) * | 2008-06-25 | 2010-01-21 | Stanford University | Radiolabeled bbn-rgd heterodimers for cancer targeting |
-
2011
- 2011-03-21 CU CU2011000067A patent/CU23950B1/es unknown
-
2012
- 2012-03-21 EP EP12716190.9A patent/EP2690107B1/en active Active
- 2012-03-21 WO PCT/CU2012/000002 patent/WO2012126441A2/es active Application Filing
- 2012-03-21 RU RU2013146690/10A patent/RU2603286C2/ru active
- 2012-03-21 US US14/005,855 patent/US9375459B2/en active Active
- 2012-03-21 KR KR1020137027692A patent/KR101958964B1/ko active IP Right Grant
- 2012-03-21 AU AU2012231427A patent/AU2012231427B2/en not_active Ceased
- 2012-03-21 BR BR112013024265-5A patent/BR112013024265B1/pt not_active IP Right Cessation
- 2012-03-21 CA CA2830325A patent/CA2830325C/en not_active Expired - Fee Related
- 2012-03-21 MX MX2013010813A patent/MX348677B/es active IP Right Grant
- 2012-03-21 ES ES12716190.9T patent/ES2644554T3/es active Active
- 2012-03-21 JP JP2014500249A patent/JP6032854B2/ja not_active Expired - Fee Related
- 2012-03-21 CN CN201280021627.4A patent/CN103534265B/zh not_active Expired - Fee Related
- 2012-03-21 AR ARP120100930A patent/AR088727A1/es active IP Right Grant
-
2013
- 2013-09-18 ZA ZA2013/07037A patent/ZA201307037B/en unknown
- 2013-10-21 CO CO13248567A patent/CO6801641A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN103534265B (zh) | 2016-06-08 |
BR112013024265B1 (pt) | 2020-12-08 |
AU2012231427A1 (en) | 2013-10-03 |
JP2014513066A (ja) | 2014-05-29 |
WO2012126441A3 (es) | 2012-11-22 |
CU23950B1 (es) | 2013-10-29 |
US9375459B2 (en) | 2016-06-28 |
EP2690107A2 (en) | 2014-01-29 |
CA2830325C (en) | 2019-09-10 |
CO6801641A2 (es) | 2013-11-29 |
KR101958964B1 (ko) | 2019-07-02 |
RU2013146690A (ru) | 2015-04-27 |
AU2012231427B2 (en) | 2016-08-04 |
JP6032854B2 (ja) | 2016-11-30 |
CN103534265A (zh) | 2014-01-22 |
ES2644554T3 (es) | 2017-11-29 |
WO2012126441A2 (es) | 2012-09-27 |
BR112013024265A2 (pt) | 2016-12-27 |
KR20140042796A (ko) | 2014-04-07 |
MX348677B (es) | 2017-06-23 |
US20140112976A1 (en) | 2014-04-24 |
RU2603286C2 (ru) | 2016-11-27 |
MX2013010813A (es) | 2013-10-07 |
AR088727A1 (es) | 2014-07-02 |
EP2690107B1 (en) | 2017-08-02 |
ZA201307037B (en) | 2014-06-25 |
CA2830325A1 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20110067A7 (es) | Péptidos cíclicos con actividad antineoplásica y antiangiogénica | |
MX2014012374A (es) | Compuestos organicos. | |
UY35142A (es) | Derivados de triazolopirazinas como inhibidores de brd4 | |
BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
NI201400108A (es) | Compuestos de heterociclilo | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
CR20140513A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
MX339805B (es) | Compuestos organicos. | |
CO6640327A2 (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
DOP2015000170A (es) | Compuestos químicos | |
CO6470899A2 (es) | 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal | |
CR20140516A (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
MX2013002948A (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
PE20160183A1 (es) | FORMULACION DE LIBERACION MODIFICADA DEL ACIDO (-)-(3aR,4S,7aR)-4-HIDROXI-4m-TOLILETINIL-OCTAHIDRO-INDOL-1-CARBOXILICO (AFQ056) | |
UY35668A (es) | Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen | |
MY173564A (en) | Cxcr7 receptor modulators | |
ES2403549R1 (es) | Co-cristales de agomelatina con formadores de co-cristales | |
MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции |